Exane Derivatives Uni Qure N.V. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Uni Qure N.V. stock. As of the latest transaction made, Exane Derivatives holds 8 shares of QURE stock, worth $46. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8
Previous 8
-0.0%
Holding current value
$46
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding QURE
# of Institutions
143Shares Held
34.9MCall Options Held
1.54MPut Options Held
389K-
Vestal Point Capital, LP New York, NY4.75MShares$27.8 Million1.59% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.65MShares$15.5 Million0.79% of portfolio
-
Abrdn PLC1.93MShares$11.3 Million0.02% of portfolio
-
Black Rock Inc. New York, NY1.93MShares$11.3 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY1.9MShares$11.1 Million0.78% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $274M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...